For years, the medical community has celebrated the arrival of lecanemab (marketed as Leqembi) as a milestone in the fight against Alzheimer’s disease. While clinical trials proved the drug could slow cognitive decline and clear toxic amyloid-beta plaques, a fundamental question remained: how exactly does an injected antibody trigger the brain to “clean itself”?

A groundbreaking study published in Nature Neuroscience has finally provided the answer. Researchers from VIB and KU Leuven have identified a specific part of the Leqembi molecule—the “Fc fragment”—as the essential key that unlocks the brain’s natural defense system. This discovery provides the first direct mechanistic explanation for how this class of drugs operates, moving the conversation from “what” it does to “how” it achieves its life-changing effects.

The Role of Microglia: The Brain’s Protective Crew

The human brain possesses its own dedicated immune system, led by specialized cells called microglia. In a healthy brain, these cells act as a cleanup crew, patrolling the neural landscape to identify and remove cellular waste and debris. However, in patients with Alzheimer’s, this system breaks down.

Toxic amyloid-beta proteins begin to clump together, forming sticky plaques that damage neurons. While microglia typically swarm around these plaques, they often become “stalled” or ineffective. They are present at the site of the damage, but they lack the specific instructions or “fuel” required to actually consume and eliminate the toxic buildup. This is where Leqembi steps in, acting as a bridge between the plaque and the cleanup crew.

The Fc Fragment: The Essential Anchor

Antibodies are often shaped like the letter “Y.” The arms of the “Y” are designed to grab onto the target—in this case, the amyloid plaques. However, the study found that merely grabbing the plaque is not enough. The “tail” of the antibody, known as the Fc fragment, is what actually triggers the immune response.

Using advanced human microglial xenograft models, the research team demonstrated that the Fc fragment serves as a biological anchor. When Leqembi attaches to a plaque, its Fc tail is exposed. Microglia then latch onto this tail through specific receptors. Without a functional Fc fragment, the researchers observed that the drug could still bind to the plaques, but the microglia remained idle. The plaques were not cleared, and the therapeutic benefit vanished.

Reprogramming the Immune Response

The study didn’t just find that the Fc fragment “wakes up” the microglia; it found that it completely “reprograms” them. Through single-cell RNA sequencing, the researchers observed that when the Fc fragment engages with microglia, it triggers a focused transcriptional program.

This program enhances several critical functions:

• Phagocytosis: The physical process of engulfing and “eating” the plaque.
• Lysosomal Degradation: The internal breakdown of the toxic protein once consumed.
• Metabolic Reprogramming: Providing the cell with the energy required for intensive cleanup.
• Antigen Presentation: Helping the immune system recognize and continue the defense.

Specifically, the study identified a protein called SPP1 (osteopontin) as a major factor induced by Leqembi. This protein appears to be a primary driver in promoting the effective removal of amyloid, providing a new target for future drug development.

Clinical Context and Safety Monitoring

While this mechanism explains why Leqembi is effective, it also highlights why medical supervision is vital. Because the drug works by activating an immune response, it can lead to inflammation. In some cases, this manifests as ARIA (Amyloid-Related Imaging Abnormalities), which involves temporary swelling or small spots of bleeding in the brain.

Understanding that the Fc fragment is the driver of this immune activity helps doctors understand why certain patients may react more strongly than others. It also explains why Leqembi is currently FDA-approved specifically for patients in the early stages of Alzheimer’s or those with Mild Cognitive Impairment (MCI). At these stages, the “cleanup crew” is still functional enough to be successfully reprogrammed.

What This Means for Families

For caregivers and families, this research offers a sense of clarity. It confirms that Leqembi is not merely a “chemical shield” but a tool that restores a vital biological process. It transforms the “stalled” immune cells of a loved one back into active protectors.

When discussing treatment options with a neurologist, families can now understand that the drug’s success depends on this cellular partnership. This also underscores the importance of the bi-weekly infusion schedule, which maintains a steady presence of these “anchors” to keep the cleanup crew working around the clock.

Looking Toward Next-Generation Therapies

The discovery that the Fc fragment is indispensable opens doors for future treatments. Scientists are now looking at ways to activate the microglial cleanup program without necessarily requiring a full antibody. This could lead to “next-generation” drugs that are even more efficient at clearing plaque with a lower risk of inflammatory side effects.

By defining the specific “cellular program” that drives plaque clearance, the VIB-KU Leuven team has provided a roadmap for the future of Alzheimer’s care. We are moving closer to a world where we don’t just slow the disease, but actively manage the brain’s environment to maintain health and cognitive function for longer.